XML 32 R19.htm IDEA: XBRL DOCUMENT v3.24.3
BUSINESS SEGMENT INFORMATION
 9 Months Ended
Sep. 30, 2024
Segment Reporting [Abstract]  
BUSINESS SEGMENT INFORMATION BUSINESS SEGMENT INFORMATION
    The Company's DIS business is the only reportable segment based on the manner in which the Chief Executive Officer, who is the Company's CODM, assesses performance and allocates resources across the organization. The DIS business provides diagnostic information services to a broad range of customers within its primary customer channels - physicians, hospitals, and patients and consumers. The DIS business accounted for greater than 95% of net revenues in 2024 and 2023.

    All other operating segments include the Company's DS businesses, which consist of its risk assessment services and healthcare information technology businesses. The Company's DS businesses offer solutions for insurers and offer solutions for healthcare providers and payers.
        
    As of September 30, 2024, substantially all of the Company’s services were provided within the United States, and substantially all of the Company’s assets were located within the United States. See Note 5 for a discussion of the Company's acquisition of LifeLabs during August 2024.

    The following table is a summary of segment information for the three and nine months ended September 30, 2024 and 2023. Segment asset information is not presented since it is not used by the CODM at the operating segment level. Operating earnings (loss) of each segment represents net revenues less directly identifiable expenses to arrive at operating income (loss) for the segment. General corporate activities included in the table below are comprised of general management and administrative corporate expenses, amortization and impairment of intangible assets and other operating income and expenses, net of certain general corporate activity costs that are allocated to the DIS and DS businesses. The accounting policies of the
segments are the same as those of the Company as set forth in Note 2 to the audited consolidated financial statements contained in the Company’s 2023 Annual Report on Form 10-K and Note 2 to the interim unaudited consolidated financial statements.
Three Months Ended September 30,Nine Months Ended September 30,
2024202320242023
Net revenues:    
DIS business$2,427 $2,228 $7,058 $6,755 
All other operating segments61 67 193 209 
Total net revenues $2,488 $2,295 $7,251 $6,964 
Operating earnings (loss):    
DIS business$407 $392 $1,200 $1,176 
All other operating segments6 8 23 26 
General corporate activities(83)(58)(238)(207)
Total operating income330 342 985 995 
Non-operating expense, net(34)(43)(109)(102)
Income before income taxes and equity in earnings of equity method investees296 299 876 893 
Income tax expense(65)(68)(205)(208)
Equity in earnings of equity method investees, net of taxes6 6 14 18 
Net income237 237 685 703 
Less: Net income attributable to noncontrolling interests11 12 36 41 
Net income attributable to Quest Diagnostics$226 $225 $649 $662